Purdue continues to protect $3 billion patent on OxyContin

Purdue Pharma and their old foe Impax Laboratories will once again face off over a generic version of OyxContin. According to this report from the San Francisco Business Times,¬†Purdue challenged Impax’s drug application for its opiate-based painkiller filed this week.¬† Back in 2007, Purdue and Impax reached a settlement which allowed Impax to sell its generic drug in limited amounts after Impax and other pharmaceutical companies claimed Purdue’s stringent patent claims were unenforceable. This comes just weeks after Purdue filed a similar suit against Watson Laboratories.

Read about other OxyContin spin-offs here.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Pharmaceutical Industry and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *